Israel's Health Ministry has issued a public warning against illegal peptides marketed for weight loss and bodybuilding, saying they may endanger health.

The ministry names five substances specifically: BPC-157, GHK-Cu, CJC-1295, TB-500 and retatrutide. The first four are research compounds with no marketing approval in Israel. Retatrutide is the outlier, a drug currently in clinical trial stages for obesity treatment that has not yet been approved for marketing there.

What is being sold, and as what

According to the ministry, these compounds are being marketed as solutions for weight loss, bodybuilding, anti-aging and improved athletic performance. That is four separate promises attached to five different molecules, which tells you something about how the market works: the pitch travels faster than the pharmacology, and the same vial gets reframed depending on who is buying.

None of them are approved for use in Israel. The ministry's framing is about the approval status and the supply chain rather than about any single claimed effect.

The risks the ministry lists

The warning is specific about harm. Use of these substances from unsupervised sources may cause serious health damage, the ministry says, including liver and kidney damage, hormonal disorders and disruptions in blood sugar levels.

Note the qualifier the ministry attached: unsupervised sources. The concern described is as much about what is actually in an unregulated vial as it is about the named peptide on the label, and that distinction gets lost in most coverage of warnings like this one.

Retatrutide is a different case

Grouping an investigational obesity drug with four research-grade peptides is a choice worth noticing. Retatrutide is being studied in clinical trials; the others are not on any comparable regulatory path in Israel. What they share is that neither category is legally sold for these uses, and both are reaching consumers anyway.

The ministry is asking the public to report sales or marketing of these substances through its Kol Habriut hotline.

Bottom line

Regulators keep arriving at the same place: the problem is not that these compounds are uninteresting, it is that the unsupervised market around them has outrun both the trials and the law. Israel has now put five names on a list, and whether reporting through a public hotline does anything about the supply is the part nobody has answered.